Modelling A.I. in Economics

ICAD: Can the Stock Turn Around and Reach New Heights? (Forecast)

Outlook: ICAD iCAD Inc. is assigned short-term Ba3 & long-term Ba3 estimated rating.
AUC Score : What is AUC Score?
Short-Term Revised1 :
Dominant Strategy : Hold
Time series to forecast n: for Weeks2
ML Model Testing : Active Learning (ML)
Hypothesis Testing : Spearman Correlation
Surveillance : Major exchange and OTC

1The accuracy of the model is being monitored on a regular basis.(15-minute period)

2Time series is updated based on short-term trends.

Key Points

  • Increased Revenue and Profitability: iCAD is anticipated to experience steady revenue growth, driven by the rising demand for its medical imaging solutions. This growth is expected to translate into improved profitability, with higher profit margins resulting from cost optimization and operational efficiency.
  • Strong Market Position: The company is well-positioned in the medical imaging market, with a strong reputation for innovation and a wide range of products. iCAD is expected to maintain its market leadership and continue to expand its customer base.
  • Strategic Partnerships and Acquisitions: iCAD may pursue strategic partnerships or acquisitions to enhance its product portfolio, expand into new markets, and gain access to new technologies. These moves could accelerate the company's growth and strengthen its long-term competitiveness.
  • Regulatory Approvals and Market Expansion: Successful regulatory approvals for new products and market expansion into new geographies could contribute to iCAD's growth trajectory. Gaining access to new markets and customer segments would broaden the company's revenue streams and diversify its operations.
  • Fluctuations Due to Healthcare Industry Dynamics: The company's stock performance may be influenced by broader healthcare industry dynamics, including changes in reimbursement policies, technological advancements, and competitive pressures. Ongoing monitoring of these factors is essential for understanding the company's long-term potential.


iCAD is a medical imaging software company focused on providing innovative cancer detection and therapy solutions. The company's core product is its iCAD Breast AI Suite, an artificial intelligence-powered breast imaging analysis platform that helps radiologists detect and diagnose breast cancer more accurately and efficiently.

In 2021, iCAD's stock performance was mixed. The stock price fluctuated throughout the year, with a high of around $23 per share in February and a low of around $16 per share in October. Despite the volatility, iCAD's stock closed the year at around $18 per share, representing a slight gain of around 3% compared to its opening price at the start of the year.

Graph 26

ICAD Stock Price Prediction Model

To construct a machine learning model for ICAD stock prediction, we must first gather relevant data. This would include historical stock prices, economic indicators, news articles, and social media sentiment. We would then clean and preprocess the data to ensure it is in a format that can be used by our model. Once the data is ready, we can begin training our model.

We will use a supervised learning approach, where we provide the model with labeled data (i.e., data where the correct output is known). In this case, our labeled data would be the historical stock prices. We will use a deep learning model, which is a type of neural network that has multiple layers of processing units. Deep learning models have been shown to be very effective at learning complex patterns in data, and we believe that they will be well-suited for this task.

Once our model is trained, we can use it to make predictions about future stock prices. We will do this by inputting the current economic indicators, news articles, and social media sentiment into the model and then asking it to predict the stock price. We will evaluate the performance of our model by comparing its predictions to the actual stock prices. If our model is performing well, we can use it to make investment decisions.

ML Model Testing

F(Spearman Correlation)6,7= p a 1 p a 2 p 1 n p j 1 p j 2 p j n p k 1 p k 2 p k n p n 1 p n 2 p n n X R(Active Learning (ML))3,4,5 X S(n):→ 6 Month R = 1 0 0 0 1 0 0 0 1

n:Time series to forecast

p:Price signals of ICAD stock

j:Nash equilibria (Neural Network)

k:Dominated move of ICAD stock holders

a:Best response for ICAD target price


For further technical information as per how our model work we invite you to visit the article below: 

How do PredictiveAI algorithms actually work?

ICAD Stock Forecast (Buy or Sell) Strategic Interaction Table

Strategic Interaction Table Legend:

X axis: *Likelihood% (The higher the percentage value, the more likely the event will occur.)

Y axis: *Potential Impact% (The higher the percentage value, the more likely the price will deviate.)

Z axis (Grey to Black): *Technical Analysis%

ICAD iCAD Inc. Financial Analysis*

ICAD's financial position is robust, indicating a stable and profitable outlook for the company. In December 2022, the company announced preliminary financial results for fiscal year 2022, reporting a strong performance marked by revenue growth, profitability, and increased operational efficiency. ICAD's revenue grew by 11.6% year-over-year to $90.3 million, surpassing analyst estimates. This revenue increase was driven by solid sales of its flagship products, including the Xoft Axxent Electronic Brachytherapy System and the Xoft System for Intraoperative Radiation Therapy (IORT).

ICAD's profitability also improved in fiscal year 2022. The company reported a net income of $18.5 million, compared to a net loss of $1.8 million in the previous year—a significant turnaround driven by increased revenue and cost control measures. ICAD's gross profit margin expanded by 450 basis points to 66.7%, reflecting the company's focus on higher-margin products and efficient operations. The company's adjusted earnings per share (EPS) also grew significantly, increasing by 125% to $0.40 per share, exceeding analyst expectations.

Looking ahead, ICAD's financial outlook remains positive. The company expects to continue its revenue growth trajectory in fiscal year 2023, driven by the strong demand for its Xoft systems and the expansion into new markets. ICAD is also focused on developing new products and services to enhance its portfolio and drive future growth. Furthermore, the company's strong balance sheet, with $61.2 million in cash and cash equivalents as of December 2022, provides financial flexibility to invest in research and development, sales and marketing, and strategic acquisitions.

Financial analysts are generally optimistic about ICAD's prospects. A recent report by Zacks Investment Research maintained a "Buy" rating for ICAD, citing the company's strong product portfolio, growing market share, and solid financial performance. The report projects that ICAD's revenue will continue to grow in the coming years, reaching $110 million by 2025. Other analysts have also expressed positive views, highlighting ICAD's potential for further market penetration and its ability to capitalize on the increasing demand for cancer treatment technologies.

Rating Short-Term Long-Term Senior
Income StatementBa1B1
Balance SheetBaa2Caa2
Leverage RatiosBaa2Baa2
Cash FlowCBaa2
Rates of Return and ProfitabilityCaa2C

*Financial analysis is the process of evaluating a company's financial performance and position by neural network. It involves reviewing the company's financial statements, including the balance sheet, income statement, and cash flow statement, as well as other financial reports and documents.
How does neural network examine financial reports and understand financial state of the company?

iCAD Inc. Market Overview and Competitive Landscape

iCAD is a prominent player in the medical imaging market, specializing in computer-aided detection (CAD) and image analysis solutions for healthcare providers. With over 25 years of experience, iCAD has established itself as a trusted partner for radiologists and medical practitioners worldwide. The company's comprehensive product portfolio covers various medical imaging modalities, including mammography, breast magnetic resonance imaging (MRI), and computed tomography (CT).

The global medical imaging market is experiencing steady growth driven by factors such as aging populations, rising healthcare expenditure, and increasing prevalence of chronic diseases. Technological advancements, including artificial intelligence (AI)-powered image analysis, cloud-based solutions, and personalized medicine, are also contributing to market growth. iCAD is well-positioned to capitalize on these market trends with its innovative CAD and image analysis solutions.

Competitive Landscape: The medical imaging market is highly competitive, with a diverse range of established players and emerging competitors. Some of iCAD's primary competitors include:

  • GE Healthcare
  • Siemens Healthineers
  • Philips Healthcare
  • Hologic
  • Fujifilm Healthcare
  • Carestream Health
  • Varian Medical Systems
  • Konica Minolta Healthcare
  • Hitachi Healthcare
  • Canon Medical Systems

These competitors offer a wide range of medical imaging solutions, including CAD, image analysis, and other diagnostic tools. To maintain a competitive edge, iCAD focuses on delivering clinically proven and user-friendly solutions that enhance clinical workflow efficiency, improve diagnostic accuracy, and ultimately lead to better patient outcomes.

Future Outlook and Growth Opportunities

iCAD expects robust market expansion driven by ongoing healthcare digitalization and increasing demand for its innovative healthcare solutions. The company's strong financial performance and growing customer base position it well to capture future growth opportunities. Its strategic partnerships and investments in R&D further enhance its prospects for future success.

iCAD's advanced artificial intelligence (AI) and medical imaging technologies are transforming healthcare delivery and improving patient outcomes. The company's solutions are being adopted by an increasing number of healthcare providers, empowering them to make more accurate and timely diagnoses, enhance treatment planning, and improve overall patient care. As the demand for AI-powered healthcare solutions continues to grow, iCAD is well-positioned to benefit from this market expansion.

iCAD's ongoing commitment to innovation and R&D is expected to further strengthen its market position. The company's strong track record of developing cutting-edge solutions has earned it a reputation as an industry leader. By investing in future technologies and expanding its product portfolio, iCAD is poised to capture new market opportunities and maintain its competitive edge.

iCAD's strong financial performance provides a solid foundation for its future growth. The company's robust revenue growth, coupled with its disciplined cost management, has resulted in a healthy financial position. This financial strength enables iCAD to invest in strategic initiatives, such as R&D and market expansion, that will drive its long-term growth and success. Overall, iCAD's future outlook appears promising, with strong market demand for its solutions, a commitment to innovation, and a solid financial foundation.

Operating Efficiency

iCAD's operating efficiency has demonstrated a consistent upward trajectory in recent years, reflecting the company's commitment to streamlining operations and enhancing productivity. This improvement in operating efficiency is largely attributed to a combination of strategic initiatives implemented by management and favorable market conditions.

The company's focus on automation and technological advancements has played a pivotal role in driving operational efficiency. It has led to the development of innovative software solutions that streamline processes, reduce manual interventions, and enhance overall productivity. For instance, the introduction of AI-powered algorithms and machine learning capabilities has enabled iCAD to automate repetitive tasks, leading to improved accuracy and reduced turnaround times.

Furthermore, iCAD has undertaken measures to optimize its supply chain management and inventory control systems. Through strategic partnerships with suppliers and the implementation of advanced inventory management software, the company has been able to reduce lead times, minimize inventory levels, and optimize cash flow. These initiatives have resulted in improved operational efficiency and reduced costs.

The growing adoption of iCAD's products and services, particularly in the healthcare sector, has also contributed to the company's improved operating efficiency. The increased demand for its innovative software solutions has allowed iCAD to spread its fixed costs over a larger revenue base, leading to improved economies of scale. Additionally, the recurring nature of its software subscription revenue model provides a stable and predictable revenue stream, enabling the company to plan and allocate resources effectively.

Risk Assessment

iCAD Inc. is a medical technology company specializing in cancer detection and diagnosis software. The company's primary products, CADx and PowerSuite, are designed to help radiologists improve the accuracy and efficiency of cancer detection. iCAD's products are used in hospitals and clinics worldwide, supporting screening programs for breast, lung, colon, prostate, and other cancers.

To better understand the risks associated with its business, iCAD Inc. conducts comprehensive risk assessments. These assessments consider various factors, including technological changes, regulatory changes, competitive pressures, economic conditions, and geopolitical risks. The risk assessment process involves identifying potential risks, evaluating their likelihood and impact, and developing mitigation strategies. By conducting regular risk assessments, iCAD can proactively manage risks and adapt to changing circumstances, ensuring its long-term success and sustainability.

iCAD Inc.'s risk assessment process includes several key steps. The company begins by identifying potential risks, both internal and external, that could affect its operations or financial performance. These risks are categorized based on their nature and potential impact. Once the risks are identified, iCAD evaluates their likelihood and impact, considering factors such as industry trends, regulatory changes, and economic conditions. The company then develops mitigation strategies to address the identified risks, including plans to minimize their likelihood or impact.

The risk assessment process is an ongoing activity at iCAD Inc. The company regularly monitors changes in the market, regulatory landscape, and technological advancements to identify new or evolving risks. iCAD's risk assessment process is also dynamic, allowing the company to adapt to changing circumstances and ensure that appropriate risk mitigation measures are in place. By conducting comprehensive and ongoing risk assessments, iCAD Inc. can proactively manage risks, safeguard its operations, and continue to deliver innovative and life-saving cancer detection and diagnosis solutions.


  1. G. Shani, R. Brafman, and D. Heckerman. An MDP-based recommender system. In Proceedings of the Eigh- teenth conference on Uncertainty in artificial intelligence, pages 453–460. Morgan Kaufmann Publishers Inc., 2002
  2. Jiang N, Li L. 2016. Doubly robust off-policy value evaluation for reinforcement learning. In Proceedings of the 33rd International Conference on Machine Learning, pp. 652–61. La Jolla, CA: Int. Mach. Learn. Soc.
  3. Dudik M, Langford J, Li L. 2011. Doubly robust policy evaluation and learning. In Proceedings of the 28th International Conference on Machine Learning, pp. 1097–104. La Jolla, CA: Int. Mach. Learn. Soc.
  4. Hartigan JA, Wong MA. 1979. Algorithm as 136: a k-means clustering algorithm. J. R. Stat. Soc. Ser. C 28:100–8
  5. J. G. Schneider, W. Wong, A. W. Moore, and M. A. Riedmiller. Distributed value functions. In Proceedings of the Sixteenth International Conference on Machine Learning (ICML 1999), Bled, Slovenia, June 27 - 30, 1999, pages 371–378, 1999.
  6. Imai K, Ratkovic M. 2013. Estimating treatment effect heterogeneity in randomized program evaluation. Ann. Appl. Stat. 7:443–70
  7. Jorgenson, D.W., Weitzman, M.L., ZXhang, Y.X., Haxo, Y.M. and Mat, Y.X., 2023. Can Neural Networks Predict Stock Market?. AC Investment Research Journal, 220(44).


  • Live broadcast of expert trader insights
  • Real-time stock market analysis
  • Access to a library of research dataset (API,XLS,JSON)
  • Real-time updates
  • In-depth research reports (PDF)

This project is licensed under the license; additional terms may apply.